Accolade's Q2 Boost: Revenue Rises, Losses Shrink, And Profitability Looms

Personalized healthcare company Accolade Inc ACCD stock is trading slightly higher after the company announced fiscal second quarter 2025 results.

The company reported a revenue increase of 10% to $106.36 million, beating the consensus of $105.01 million. Loss per share of $0.30 beat the consensus loss of $0.44.

Adjusted gross profit rose 17% Y/Y to $50.30 million. Adjusted EBITDA loss narrowed to $2.83 million from $8.76 million a year ago.

As of August 31, ACCD’s cash and cash equivalents stood at $234.35 million. 

“As we enter the second half of fiscal year 2025, we are well positioned to deliver our first full year of Adjusted EBITDA profitability and positive cash flow,” said Rajeev Singh, Accolade Chair and CEO.

Outlook: Accolade expects third-quarter revenues of $104 million—$107 million (versus the $110.16 million estimate) and an adjusted EBITDA loss of $3 million—$5 million.

The company reiterated fiscal 2025 revenues of $460 million—$475 million versus consensus of $466.97 million and adjusted EBITDA of $15 million—$20 million.

Accolade stock plunged over 67% year-to-date as the analysts cut their price targets on the stock during the last two quarterly prints.

Price Action: ACCD stock is up 0.25% at $3.98 premarket at the last check Tuesday.